Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.57 |
| ▸ | CTSL | P07711 | 7/20 | 0.53 |
| ▸ | CTSS | P25774 | 7/20 | 0.53 |
| ▸ | CTSB | P07858 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KYNU | Q16719 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961276 | 1.00 | CTSK (0.57) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL16847591 | 0.93 | CTSL (0.62) | CTSKCTSLCTSSCTSBSIRT2 | |
| SCHEMBL8098620 | 0.90 | CTSL (0.55) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL5885617 | 0.90 | CTSK (0.53) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL1701577 | 0.90 | CTSL (0.55) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL12406443 | 0.90 | CTSK (0.56) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL1667005 | 0.89 | CTSK (0.52) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL19017976 | 0.88 | CTSK (0.55) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL3709555 | 0.88 | CTSK (0.55) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL629856 | 0.88 | CTSL (0.67) | CTSKCTSLCTSSCTSBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2738164-A1 | Synthesis of an intermediate of an antiviral compound | Dipharma Francis S.r.l. (IT) | 2014-06-04 | — | — | EP | disclosed |
| US-20140148574-A1 | SYNTHESIS OF AN INTERMEDIATE OF AN ANTIVIRAL COMPOUND | DIPHARMA FRANCIS S.R.L. (IT) | 2014-05-29 | — | — | US | disclosed |
| US-8637457-B2 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-8399615-B2 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-8383858-B2 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-26 | — | — | US | disclosed |
| US-20100298568-A1 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-25 | — | — | US | disclosed |
| US-7776887-B2 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100174077-A1 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100063252-A1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED | 2010-03-11 | — | — | US | disclosed |
| US-20070244334-A1 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| WO-2007109023-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING STERIC COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298568-A1 | Processes and intermediates for preparing steric compounds | REV1, HSD11B1, CYP11B1 | CTSK 2555/4885CTSL 2031/4885CTSS 1351/4885 |
| US-20140148574-A1 | SYNTHESIS OF AN INTERMEDIATE OF AN ANTIVIRAL COMPOUND | ZC3HAV1, PREP, EIF2AK2 | CTSK 132/4885CTSL 69/4885CTSS 61/4885 |
| US-20100063252-A1 | PROCESSES AND INTERMEDIATES | TFPI, SPINT2, SERPINB1 | CTSK 91/4885CTSL 17/4885CTSS 38/4885 |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | PRSS1, CTRL, TMPRSS2 | CTSK 86/4885CTSL 19/4885CTSS 8/4885 |
| US-20100174077-A1 | Processes and intermediates | TFPI, SPINT2, SERPINB1 | CTSK 91/4885CTSL 17/4885CTSS 38/4885 |
| US-20070244334-A1 | Processes and intermediates for preparing steric compounds | REV1, HSD11B1, CYP11B1 | CTSK 2555/4885CTSL 2031/4885CTSS 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.